Passage Bio to Merge with Remix Therapeutics in Reverse Merger, Existing Shareholders Heavily Diluted

summarizeSummary

Passage Bio will merge with private Remix Therapeutics in a reverse merger, resulting in significant dilution for existing shareholders who will own ~7.4% of the combined company. A $100 million financing will fund the new entity, which will focus on Remix's pipeline.

check_boxKey Events · M&A and Partnerships · PASG

• Reverse Merger Agreement

  Passage Bio, Inc. has entered into a definitive merger agreement with private company Remix Therapeutics, Inc. The combined company will operate as Remix Therapeutics, Inc. and trade on Nasdaq under the ticker symbol 'RMTX'.

• Significant Shareholder Dilution

  Pre-merger Passage Bio shareholders are expected to own approximately 7.4% of the combined company, while pre-merger Remix stockholders (including new investors) will own approximately 92.6%.

• Concurrent $100 Million Financing

  Remix has secured commitments for an oversubscribed private placement financing of approximately $100 million, expected to close immediately prior to the merger. This capital is anticipated to fund operations into 2028.

• Contingent Value Rights (CVRs)

  Passage Bio shareholders of record at the closing date will receive CVRs, entitling them to a pro rata portion of certain net proceeds from milestones associated with Passage Bio's out-licensed pediatric gene therapy pipeline assets. CVRs are non-transferable and not listed.

auto_awesomeAnalysis · PASG · Life Sciences

Passage Bio, a company previously facing a 'going concern' warning and significant workforce reductions, will undergo a reverse merger with private company Remix Therapeutics. This transaction is highly dilutive for existing Passage Bio shareholders, who are expected to own only approximately 7.4% of the combined entity. The combined company will operate under the Remix Therapeutics name and leadership, focusing on Remix's RNA processing modulation pipeline. A concurrent $100 million private placement financing will provide the combined company with a cash runway into 2028. Existing Passage Bio shareholders will receive Contingent Value Rights (CVRs) for potential future proceeds from Passage Bio's out-licensed legacy assets, though these are speculative and non-transferable. This event represents a complete strategic pivot and a lifeline for Passage Bio, but at a substantial cost to its current shareholders.